Pharmaceutical News RSS Feed - Pharmaceutical News

Glide Pharma announces successful completion of pre-clinical proof-of-concept study with novel solid formulation of octreotide acetate

Glide Pharma announces successful completion of pre-clinical proof-of-concept study with novel solid formulation of octreotide acetate

Glide Pharma, the pharmaceutical development and device company focused on solid dose formulations of therapeutics and vaccines, today announced that its novel solid formulation of octreotide acetate achieved successful results in a pre-clinical proof-of-concept study comparing it with the currently marketed liquid product (Sandostatin®). [More]
Researchers prove that CD27 drug is true alternative against malaria

Researchers prove that CD27 drug is true alternative against malaria

Researchers from the Universitat Politècnica de Catalunya · BarcelonaTech (UPC), the Instituto de Química Mèdica (IQM-CSIC) and the University of Glasgow have proved that the CD27 drug is a true alternative against malaria. [More]
Drug for reduction of abdominal fat in HIV patients may also reduce fatty liver disease

Drug for reduction of abdominal fat in HIV patients may also reduce fatty liver disease

The only drug to receive FDA approval for reduction of the abdominal fat deposits that develop in some patients receiving antiviral therapy for HIV infection may also reduce the incidence of fatty liver disease in such patients. [More]
Common genetic variation in gene may modify cardiovascular benefit of aspirin

Common genetic variation in gene may modify cardiovascular benefit of aspirin

Aspirin is the gold standard for antiplatelet therapy and a daily low-dose aspirin is widely prescribed for the prevention of cardiovascular disease. [More]
Study confirms link between antipsychotic medication and slight decrease in brain volume

Study confirms link between antipsychotic medication and slight decrease in brain volume

A study published today has confirmed a link between antipsychotic medication and a slight, but measureable, decrease in brain volume in patients with schizophrenia. [More]
National Med Care partners with Taking You Forward for marketing pharmaceutical products in the U.S.

National Med Care partners with Taking You Forward for marketing pharmaceutical products in the U.S.

Richmond Private Equity Group Limited announced today that its "portfolio company", National Med Care Ltd, a Salt Lake City Utah, based pharmaceutical marketing firm has entered into an agreement with Taking You Forward Inc., a Cebu Philippines based BPO firm to form a joint venture for the marketing of its compound pharmaceutical products in the United States. [More]
Phase II study reveals potential biomarker for HIV vaccine

Phase II study reveals potential biomarker for HIV vaccine

Further analysis of a Phase II study of therapeutic HIV vaccine candidate Vacc-4x revealed a potential biomarker associated with participants who experienced a more profound viral load reduction after receiving the vaccine. [More]
FDA approves Ruconest for treatment of acute attacks in adolescent patients with HAE

FDA approves Ruconest for treatment of acute attacks in adolescent patients with HAE

The U.S. Food and Drug Administration yesterday approved Ruconest, the first recombinant C1-Esterase Inhibitor product for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema (HAE). [More]
Splice-switching oligonucleotide drugs alter editing of gene transcript

Splice-switching oligonucleotide drugs alter editing of gene transcript

In splice-switching, an innovative therapeutic approach, targeted oligonucleotide drugs alter the editing of a gene transcript to produce the desired form of a protein. [More]
Asthma inhalers may suppress children's growth

Asthma inhalers may suppress children's growth

Corticosteroid drugs that are given by inhalers to children with asthma may suppress their growth, evidence suggests. Two new systematic reviews published in The Cochrane Library focus on the effects of inhaled corticosteroid drugs (ICS) on growth rates. [More]
New study finds highest rates of decline in prescription drug misuse nationwide

New study finds highest rates of decline in prescription drug misuse nationwide

Five states that have implemented multi-faceted prescription drug abuse prevention programs in recent years showed the highest rate of decline in prescription drug misuse rates nationwide, according to a new study issued today by Quest Diagnostics, the world's leading provider of diagnostic information services. [More]
Ruthigen treats first human subjects with leading drug candidate RUT58-60

Ruthigen treats first human subjects with leading drug candidate RUT58-60

Ruthigen, Inc., today announced that it has treated the first human subjects with its leading drug candidate RUT58-60 in a 30 patient, 21-day skin irritation trial, which is expected to be completed in August 2014. [More]
Phase 2 dose-ranging study of AYX1 for prevention of post-surgical pain

Phase 2 dose-ranging study of AYX1 for prevention of post-surgical pain

Adynxx, developer of a first-in-class platform of therapeutics to address pain at its molecular roots, announced today that the first patient was dosed in ADYX-003, a Phase 2 dose-ranging study of AYX1, an investigational drug candidate for the prevention of post-surgical pain. [More]

FDA designated Astellas’ isavuconazole as QIDP for treatment of invasive candidiasis

Astellas today announced that the U.S. Food and Drug Administration (FDA) designated isavuconazole as a Qualified Infectious Disease Product (QIDP) for the treatment of invasive candidiasis, a life-threatening, invasive fungal infection. [More]
First publication describing use of CytoSorb during cardiac surgery

First publication describing use of CytoSorb during cardiac surgery

CytoSorbents Corporation, a critical care immunotherapy company commercializing its CytoSorb® cytokine adsorber in multiple countries worldwide, announced the PDF availability of the first publication describing the use of CytoSorb® intra-operatively during cardiac surgery at the Ludwig Maximilian University of Munich Hospital - Grosshadern Campus, in Germany. [More]
FDA grants Breakthrough Therapy designation to Boehringer Ingelheim’s nintedanib

FDA grants Breakthrough Therapy designation to Boehringer Ingelheim’s nintedanib

Boehringer Ingelheim Pharmaceuticals, Inc. today announced that the U.S. Food & Drug Administration (FDA) has granted Breakthrough Therapy designation to nintedanib, an investigational therapy currently under FDA review for the treatment of people with idiopathic pulmonary fibrosis (IPF). [More]
New analysis provides information about which medications best after different types of surgery

New analysis provides information about which medications best after different types of surgery

Current guidelines do not distinguish between aspirin and more potent blood thinners for protecting against blood clots in patients who undergo major orthopedic operations, leaving the decision up to individual clinicians. [More]
Once-a-day pill for patients experiencing opioid-induced constipation

Once-a-day pill for patients experiencing opioid-induced constipation

Opioids - strong morphine-based painkillers - are widely prescribed to patients experiencing chronic severe pain. While these drugs are very effective for treating and managing pain, they have one particularly bothersome side effect: constipation. [More]
GSK begins shipment of flu vaccines to U.S. for the upcoming 2014-15 season

GSK begins shipment of flu vaccines to U.S. for the upcoming 2014-15 season

GSK announced today it has begun shipping FLUARIX QUADRIVALENT (Influenza Vaccine) doses to U.S. healthcare providers. This is the first shipment of GSK’s U.S. flu vaccine supply for the flu season, following licensing and lot-release approval from the U.S. Food and Drug Administration’s Center for Biologics Evaluation and Research. [More]
Cholesterol-lowering statins may prolong lives of people with diabetic cardiovascular disease

Cholesterol-lowering statins may prolong lives of people with diabetic cardiovascular disease

Heart disease and stroke are the leading causes of death and disability among people with Type 2 diabetes. In fact, at least 65 percent of people with diabetes die from some form of heart disease or stroke, according to the American Heart Association. [More]